Study on TACE and Sorafenib for Liver Cancer Before Transplant
Author Information
Author(s): Katrin Hoffmann, Hanno Glimm, Boris Radeleff, Goetz Richter, Christoph Heining, Irini Schenkel, Anita Zahlten-Hinguranage, Peter Schirrmacher, Jan Schmidt, Markus Büchler, Dirk Jaeger, Christof Kalle, Peter Schemmer
Primary Institution: Ruprecht-Karls-University, Heidelberg, Germany
Hypothesis
Does combining transarterial chemoembolization (TACE) with Sorafenib improve outcomes for patients with hepatocellular cancer before liver transplantation compared to TACE plus placebo?
Conclusion
The study aims to determine if TACE combined with Sorafenib is more effective than TACE alone in treating hepatocellular cancer before liver transplantation.
Supporting Evidence
- Hepatocellular carcinoma is a leading cause of cancer death worldwide.
- TACE is the standard treatment for patients with hepatocellular carcinoma awaiting liver transplantation.
- Sorafenib has been shown to improve survival in patients with advanced hepatocellular carcinoma.
Takeaway
This study is testing if a cancer treatment called TACE works better when combined with a pill called Sorafenib for patients waiting for a liver transplant.
Methodology
The study is a double-blinded, controlled, prospective, randomized multi-centre phase III trial comparing TACE plus Sorafenib to TACE plus placebo.
Potential Biases
Potential biases may arise from the randomization process and patient selection criteria.
Limitations
The study may have a high drop-out rate, and results may not be generalizable to all patients with hepatocellular carcinoma.
Participant Demographics
Patients over 18 years of age with histologically confirmed hepatocellular carcinoma, without extrahepatic disease.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website